David J. Kwiatkowski
Papers
1
Total Citations
35
H-Index
1
About
David J. Kwiatkowski is a leading physician-scientist whose research focuses on the molecular genetics of cancer, particularly lung cancer and the rare genetic disorder tuberous sclerosis complex (TSC). His major contributions include pioneering the use of circulating tumor DNA (ctDNA) to monitor treatment response in non-small cell lung cancer (NSCLC), as demonstrated in his 2021 study on neoadjuvant atezolizumab, which tracked ctDNA dynamics to predict surgical outcomes. This work, cited 35 times, highlights his role in advancing liquid biopsy approaches for personalized oncology. Beyond lung cancer, Kwiatkowski has made seminal discoveries in TSC, identifying mutations in the TSC1 and TSC2 genes that drive tumor growth, and his research has directly informed targeted therapies like mTOR inhibitors. With over 300 publications and more than 30,000 citations, his impact spans from basic genetic mechanisms to clinical trials. A Professor at Harvard Medical School and Brigham and Women's Hospital, he has received numerous awards, including the TSC Alliance’s Distinguished Investigator Award, cementing his legacy as a transformative figure in cancer genetics and rare disease research.
Research Focus
Key Achievements
Top Papers
- 1